The latest announcement is out from Inspira Technologies Oxy BHN ( (IINN) ).
On April 23, 2025, Inspira Technologies announced a significant milestone in the in-vivo testing of its VORTX technology, achieving over 99% gas exchange efficiency. This breakthrough, conducted at Israel’s Institute of Animal Research, confirms the technology’s potential to transform acute respiratory care by reducing blood trauma associated with traditional oxygenation methods. The success of this IIA-funded trial underscores Inspira’s innovative capabilities and commitment to advancing life-support technology.
Spark’s Take on IINN Stock
According to Spark, TipRanks’ AI Analyst, IINN is a Underperform.
The overall stock score reflects significant financial instability, as indicated by ongoing losses and reliance on external funding. The technical analysis shows bearish sentiment, with the stock under pressure. Valuation is challenging due to negative earnings and lack of dividend yield, making the stock less appealing to investors.
To see Spark’s full report on IINN stock, click here.
More about Inspira Technologies Oxy BHN
Inspira Technologies Oxy B.H.N. Ltd. is a pioneer in innovative life-support and diagnostic technologies. The company is developing products such as the INSPIRA ART500 system, which aims to revolutionize critical care by enabling patients to remain awake during treatment while stabilizing oxygen levels without mechanical ventilation. Additionally, the FDA-cleared INSPIRA ART100 system is approved for Cardiopulmonary Bypass procedures in the U.S. and Israel. Inspira is also working on the HYLA blood sensor technology for continuous, real-time blood monitoring.
YTD Price Performance: -45.24%
Average Trading Volume: 729,782
Technical Sentiment Signal: Buy
Current Market Cap: $14.73M
For an in-depth examination of IINN stock, go to TipRanks’ Stock Analysis page.